Summary
Althoughras mutations are infrequent (approximately 5%) in breast cancers, there is considerable evidence that suggests that the pathways which Ras services may still be deregulated in breast cancer cells. The recent identification of many of the components of the Ras signal transduction pathway has defined a network of proto-oncogene proteins controlling diverse signaling events that regulate cell growth and differentiation. Consequently, mutations that perturb the function of any one component of this signal pathway may trigger the same oncogenic events as mutation ofras itself. Moreover, several Ras-related proteins have recently been demonstrated to possess the ability to trigger malignant transformation via signaling pathways shared with Ras proteins. Thus, it is possible that the aberrant function of Ras-related proteins may contribute to breast cancer development. Consequently, it is important not to dismiss the Ras pathway in the development of breast cancer merely because of the infrequent detection of mutations inras itself, but rather to consider the influence of aberrations upstream or downstream of Ras and of certain Ras-related proteins in the development of breast cancer. Finally, the critical importance of components upstream and downstream of Ras provides additional targets for rational drug design approaches to block the aberrant function of Ras signaling in human tumors.
Similar content being viewed by others
References
Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348:125–132, 1990
Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 349:117–126, 1990
Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366:643–654, 1993
Bortner DM, Langer SJ, Ostrowski MC: Non-nuclear oncogenes and the regulation of gene expression in transformed cells. Crit Rev Oncogenesis 4:137–160, 1993
Downward J: Regulatory mechanisms forras proteins. BioEssays 14:177–184, 1992
Chang EH, Furth ME, Scolnick EM, Lowy DR: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297:479–483, 1982
Barbacid M:ras genes. Annu Rev Biochem 56:779–827, 1987
Bos JL:ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689, 1989
Clark GJ, Der CJ: Oncogenic activation ofRas proteins.In: Dickey BF, Birnbaumer L (eds) GTPases in Biology, I. Springer Verlag, Berlin, 1994, pp 259–288
Sukumar S:ras oncogenes in chemical carcinogenesis.In: Vogt PK (ed) Oncogenes and Retroviruses, Selected Reviews (148th ed). Springer Verlag, Berlin, 1989, pp 93–114
Albini A, Graf J, Kitten GT, Kleinman HK, Martin GR, Veillette A, Lippman ME: 17β-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci USA 83: 8182–8186, 1986
Sukumar S, Carney WP, Barbacid M: Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science 240: 524–526, 1988
Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJP, Koszaika M, Russo J: Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogen 4:25–35, 1991
Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49:465–475, 1987
Hand PH, Vilasi V, Thor A, Ohuchi N, Schlom J: Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. J Natl Cancer Inst 79:59–65, 1987
Spandidos DA: Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer Res 7:991–996, 1987
Clair T, Miller WR, Cho-Chung YS: Prognostic significance of the expression of aras protein with a molecular weight of 21,000 in human breast cancer. Cancer Res 47:5290–5293, 1987
Khosravi-Far R, Der CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 13:67–89, 1994
Prendergast GC, Gibbs JB: Pathways of Ras function: connections to the actin cytoskeleton. Adv Cancer Res 62:19–63, 1993
Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268:14553–14556, 1993
Bishop JM: The molecular genetics of cancer. Science 235:305–311, 1987
Bishop JM: Molecular themes in oncogenesis. Cell 64:235–248, 1991
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell 64:281–302, 1991
Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841–852, 1994
Xu G, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F: The catalytic domain of the neurofibromatosis type 1 gene product stimulatesras GTPase and complementsira mutants ofS. cerevisiae. Cell 63:835–841, 1990
Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, Innis MA, McCormick F: The GAP-related domain of the neurofibromatosis type 1 gene product interacts withras p21. Cell 63:843–849, 1990
Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F: TheNF1 locus encodes a protein functionally related to mammalian GAP and yeastIRA proteins. Cell 63:851–859, 1990
DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR: Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265–273, 1992
Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation ofras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713–715, 1992
Quilliam LA, Huff SY, Rabun KM, Wei W, Broek D, Der CJ: Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. Proc Natl Acad Sci USA 91:8512–8515, 1994
Barlat I, Schweighoffer F, Chevallier-Multon MC, Duchesne M, Fath I, Landais D, Jacquet M, Tocque B: TheSaccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells. Oncogene 8:215–218, 1993
Cen H, Papageorge AG, Vass WC, Zhang K, Lowy DR: Regulated and constitutive activity by CDC25Mm (GRF), a ras-specific exchange factor. Mol Cell Biol 13:7718–7724, 1993
Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45–51, 1993
Toi M, Hamada Y, Nakamura T, Mukaida H, Suehiro S, Wada T, Toge T, Niimoto M, Hattori T: Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion. Int J Cancer 43:220–225, 1989
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177–182, 1987
McCormick F: How receptors turn Ras on. Nature 363:15–16, 1993
Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252:668–674, 1991
Mayer BJ, Baltimore D: Signalling through SH2 and SH3 domains. Trends Cell Biol 3:8–13, 1993
Pawson T: SH2 and SH3 domains. Curr Op Cell Biol 2:432–437, 1992
Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG, Girge RB, Fajardo JE, Chou MM, Hanafusa H, Schaffhausen B, Cantley LC: SH2 domains recognize specific phosphopeptide sequences. Cell 72:767–778, 1993
Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL: Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76:933–945, 1994
Pazin MJ, Williams LT: Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci 17:374–378, 1992
Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764–773, 1994
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185, 1993
Arlinghaus RB: Multiple BCR-related gene products and their proposed involvement in ligand-induced signal transduction pathways. Mol Carcinogen 5:171–173, 1992
Hall A:ras and GAP — who's controlling whom? Cell 61:921–923, 1990
Haubruck H, McCormick F: Ras p21: effects and regulation. Biochim Biophys Acta 1072:215–229, 1991
Roberts TM: A signal chain of events. Nature 360: 534–535, 1992
Clark GJ, Quilliam LA, Hisaka MM, Der CJ: Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. Proc Natl Acad Sci USA 90:4887–4891, 1993
Duchesne M, Schweighoffer F, Parker F, Clerc F, Frobert Y, Thang MN, Tocqué B: Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling. Science 259:525–528, 1993
Martin GA, Yatani A, Clark R, Conroy L, Polakis P, Brown AM, McCormick F: GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents. Science 255:192–194, 1992
Johnson MR, DeClue JE, Felzmann S, Vass WC, Xu G, White R, Lowy DR: Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 14: 641–645, 1994
NNFF International NF1 Genetic Consortium, Vol. 2, No.3
Friedman E, Gejman PV, Martin GA, McCormick F: Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumors. Nature Genetics 5:242–247, 1993
Moodie SA, Willumsen BM, Weber MJ, Wolfman A: Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase. Science 260:1658–1661, 1993
Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M: Complex formation between RAS and RAF and other protein kinases. Proc Natl Acad Sci USA 90: 6213–6217, 1993
Vojtek AB, Hollenberg SM, Cooper JA: Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 205–214, 1993
Zhang X, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS, Bruder JT, Rapp UR, Avruch J: Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364:308–313, 1993
Warne PH, Viciana PR, Downward J: Direct interaction of Ras and the amino-terminal region of Raf-1in vitro. Nature 364:352–355, 1993
Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF: Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463–1467, 1994
Leevers SJ, Paterson HF, Marshall CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411–414, 1994
Leevers SJ, Marshall CJ: MAP kinase regulation — the oncogene connection. Trends Cell Biol 2:283–286, 1992
Crews CM, Erikson RL: Extracellular signals and reversible protein phosphorylation: what to mek of it all. Cell 74:215–217, 1993
Blenis J: Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 90:5889–5892, 1993
Johnson GL, Vaillancourt RR: Sequential protein kinase reactions controlling cell growth and differentiation. Current Opin Cell Biol 6:230–238, 1994
Stanton VP Jr, Cooper GM: Activation of human raf transforming genes by deletion of normal aminoterminal coding sequences. Mol Cell Biol 7:1171–1179, 1987
Fabian JR, Daar IO, Morrison DK: Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13:7170–7179, 1993
Brunner D, Oellers N, Szabad J, Biggs WH III, Zipursky SL, Hafen E: A gain-of-function mutation inDrosophila MAP kinase activates multiple receptor tyrosine kinase signaling pathways. Cell 76:875–888, 1994
Bokoch GM, Der CJ: Emerging concepts in theRas superfamily of GTP-binding proteins. FASEB J 7: 750–759, 1993
Goud B, McCaffrey M: Small GTP-binding proteins and their role in transport. Cell Biol 3:626–633, 1991
Hall A: Ras-related GTPases and the cytoskeleton. Mol Biol Cell 3:475–479, 1992
Bischoff FR, Ponstingl H: Mitotic regulator protein RCC1 is complexed with a nuclearras-related polypeptide. Proc Natl Acad Sci USA 88:10830–10834, 1991
Moore MS, Biobel G: The GTP-binding protein Ran/TC4 is required for protein import into the nucleus. Nature 365:661–663, 1993
Ren M, Drivas G, D'Eustachio P, Rush MG: Ran/TC4: a small nuclear GTP-binding protein that regulates DNA synthesis. J Cell Biol 120:313–323, 1993
Graham SM, Cox AD, Drivas G, Rush MR, D'Eustachio P, Der CJ: Aberrant function of the Ras-related TC21/R-Ras2 protein triggers malignant transformation. Mol Cell Biol 14:4108–4115, 1994
Cox AD, Brtva TR, Lowe DG, Der CJ: R-Ras induces malignant, but not morphologic, transformation of NIH 3T3 cells. Oncogene 9:3281–3288, 1994
Drivas GT, Shih A, Coutavas E, Rush MG, D'Eustachio P: Characterization of four novelras-like genes expressed in a human teratocarcinoma cell line. Mol Cell Biol 10:1793–1798, 1990
Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075–6086, 1990
Rey I, Taylor-Harris P, van Erp H, Hall A: R-ras interacts with rasGAP, neurofibromin, and c-raf but does not regulate cell growth or differentiation. Oncogene 9:685–692, 1994
Fernandez-Sarabia MJ, Bischoff JR: Bc1-2 associates with theras-related protein R-ras p23. Nature 366: 274–275, 1993
Gibbs JB: Ras C-terminal processing enzymes — new drug targets. Cell 65:1–4, 1991
Khosravi-Far R, Cox AD, Kato K, Der CJ: Protein prenylation: key to ras function and cancer intervention? Cell Growth and Diff 3:461–469, 1992
Hancock JF: Anti-Ras drugs come of age. Curr Biol 3:770–772, 1993
Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355–386, 1992
Giannakouros T, Magee AI: Protein prenylation and associated modifications. CRC Rev 31:8030–8035, 1992
Cox AD, Der CJ: Protein prenylation: more than just glue? Curr Op Cell Biol 4:1008–1016, 1992
Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403–6407, 1992
Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS: Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62:81–88, 1990
Reiss Y, Stradley SJ, Gierasch LM, Brown MS, Goldstein JL: Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 88:732–736, 1991
Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM: Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 266: 15575–15578, 1991
Farnsworth CC, Gelb MH, Glomset JA: Identification of geranylgeranyl-modified proteins in HeLa cells. Science 247:320–322, 1990
Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC: Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci USA 88:9668–9670, 1991
Casey PJ: Biochemistry of protein prenylation. J Lipid Res 33:1731–1740, 1992
James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937–1942, 1993
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition ofras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934–1937, 1993
Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD: Peptidomimetic inhibitors ofras farnesylation and function in whole cells. J Biol Chem 268: 18415–18418, 1993
Nigam M, Seong C-M, Qian Y, Hamilton AD, Sebti SM: Potent inhibition of human tumor p21ras farnesyltransferase byA 1 A 2-lacking p21ras CA 1 A 2 X peptidomimetics. J Biol Chem 268:20695–20698, 1993
Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA, Der CJ: The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. J Biol Chem 269:19203–19206, 1994
Mayer BJ, Ren R, Clark KL, Baltimore D: A putative modular domain present in diverse signaling proteins. Cell 73:629–630, 1993
Musacchio A, Gibson T, Rice P, Thompson J, Saraste M: The PH domain: a common piece in the structural patchwork of signaling proteins. Trends Biochem Sci 18:343–348, 1993
Kolch W, Heidecker G, Lloyd P, Rapp UR: Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426–428, 1991
Westwick JK, Cox AD, Der CJ, Cobb MH, Hibi M, Karin M, Brenner DA: Oncogenic Ras activates c-Jun via a separate pathway from the activation of extra-cellular-signal regulated kinases. Proc Natl Acad Sci USA 91:6030–6034, 1994
Wick M, Lucibello FC, Müller R: Inhibition of Fos-and Ras-induced transformation by mutant Fos proteins with structural alterations in functionally different domains. Oncogene 7:859–867, 1992
Granger-Schnarr M, Benusiglio E, Schnarr M, Sassone-Corsi P: Transformation and transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial repressor. Proc Natl Acad Sci USA 89: 4236–4239, 1992
Langer SJ, Bortner DM, Roussel MF, Sherr CJ, Ostrowski MC: Mitogenic signaling by colony-stimulating factor 1 andras is suppressed by theets-2 DNA-binding domain and restored bymyc overexpression. Mol Cell Biol 12:5355–5362, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clark, G.J., Der, C.J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Tr 35, 133–144 (1995). https://doi.org/10.1007/BF00694753
Issue Date:
DOI: https://doi.org/10.1007/BF00694753